Cowen Lowers Sema4 (NASDAQ:SMFR) Price Target to $3.00

Sema4 (NASDAQ:SMFRGet Rating) had its target price lowered by research analysts at Cowen from $5.00 to $3.00 in a research note issued to investors on Tuesday, The Fly reports. The firm currently has an “outperform” rating on the stock. Cowen’s target price would indicate a potential upside of 302.68% from the stock’s previous close.

Several other research analysts have also recently issued reports on SMFR. Jefferies Financial Group cut Sema4 from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $4.00 to $2.00 in a research note on Tuesday, August 16th. BTIG Research reduced their price objective on Sema4 from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, August 18th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $3.25.

Sema4 Trading Down 15.3 %

Shares of NASDAQ:SMFR opened at $0.75 on Tuesday. Sema4 has a 52-week low of $0.65 and a 52-week high of $7.57. The stock has a market cap of $281.05 million, a price-to-earnings ratio of -0.80 and a beta of 1.96. The company has a quick ratio of 1.76, a current ratio of 1.97 and a debt-to-equity ratio of 0.02. The business has a 50-day moving average price of $0.96 and a 200-day moving average price of $1.42.

Sema4 (NASDAQ:SMFRGet Rating) last announced its quarterly earnings data on Monday, August 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). Sema4 had a negative return on equity of 61.71% and a negative net margin of 89.71%. The firm had revenue of $36.17 million during the quarter, compared to analysts’ expectations of $71.90 million. Equities analysts predict that Sema4 will post -0.91 EPS for the current year.

Institutional Trading of Sema4

Several hedge funds and other institutional investors have recently bought and sold shares of SMFR. Corvex Management LP grew its holdings in Sema4 by 254.2% during the second quarter. Corvex Management LP now owns 15,937,500 shares of the company’s stock worth $20,081,000 after acquiring an additional 11,437,500 shares during the period. Casdin Capital LLC grew its holdings in Sema4 by 228.8% in the second quarter. Casdin Capital LLC now owns 16,437,500 shares of the company’s stock valued at $20,711,000 after purchasing an additional 11,437,500 shares during the period. Deerfield Management Company L.P. Series C grew its holdings in Sema4 by 36.1% in the second quarter. Deerfield Management Company L.P. Series C now owns 18,848,488 shares of the company’s stock valued at $23,749,000 after purchasing an additional 5,000,000 shares during the period. Decheng Capital Management III Cayman LLC acquired a new stake in Sema4 in the first quarter valued at approximately $10,496,000. Finally, Vanguard Group Inc. grew its holdings in Sema4 by 67.6% in the first quarter. Vanguard Group Inc. now owns 5,518,333 shares of the company’s stock valued at $16,941,000 after purchasing an additional 2,226,502 shares during the period.

Sema4 Company Profile

(Get Rating)

Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services.

Featured Stories

The Fly logo

Analyst Recommendations for Sema4 (NASDAQ:SMFR)

Receive News & Ratings for Sema4 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sema4 and related companies with MarketBeat.com's FREE daily email newsletter.